Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare neurometabolic disorder characterized by childhood-onset dystonia that shows a dramatic and sustained response to low doses of levodopa (L-dopa) and that may be associated with parkinsonism at an older age.
No HPO annotations are available for this condition.
GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD), the major form of DRD, is a clinical syndrome characterized by childhood-onset dystonia and a dramatic and sustained response (complete or near-complete responsiveness of symptoms) to relatively low doses of levodopa. The perinatal and postnatal periods are normal, as is early motor development. Symptoms and signs. Initial symptoms in most individuals with childhood-onset GTPCH1-deficient DRD are gait difficulties attributable to dystonia in the legs, typically flexion-inversion (equinovarus posture) of the foot. Affected individuals have a tendency to fall. A relatively small number of individuals have onset with arm dystonia, postural tremor of the hand, or slowness of movements.
GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) should be suspected in individuals with the following characteristics [, , , , , ]:
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
No approved treatments are currently available for autosomal dominant dopa-responsive dystonia. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Examination by a movement disorder specialist at least several times yearly is recommended.
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
1 publication has been identified in PubMed for autosomal dominant dopa-responsive dystonia. Research spans Review / Meta-Analysis (100%).
Gabaldon-Albero A (2024). [PMID: 38791237](https://pubmed.ncbi.nlm.nih.gov/38791237/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
European rare disease database
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
A dramatic and sustained response to low doses of levodopa in dopa-responsive dystonia (DRD) distinguishes this disorder from cerebral palsy, spastic paraplegia, and all other forms of dystonia, including early-onset primary dystonia (DYT1). (For a differential diagnosis of dystonia, see Dystonia Overview.) The major differential diagnoses of GTPCH1-deficient DRD are summarized in and include TH-deficient DRD, SR-deficient DRD (rare), and early-onset Parkinson disease. Table 2. Disorders to Consider in the Differential Diagnosis of GTPCH1-Deficient DRD
DiffDx Disorder | Gene(s) | MOI | Clinical Features of DiffDx Disorder |
|---|---|---|---|
Overlapping w/GTPCH1-deficient DRD | Distinguishing from GTPCH1-deficient DRD Tyrosine hydroxylase-deficient DRD (DYT5b; DYT-TH) | TH1 | AR |
SPR | AR4 | 1 family reported w/strikingly mild sepiapterin reductase deficiency phenotype (DRD w/o motor cognitive delay)5,6; Sepiapterin reductase deficiency w/mild findings may mimic GTPCH1-deficient DRD.; Remarkable response to levodopa; Diurnal fluctuation of symptoms | concentration of BP is assoc w/nl concentration of NP in CSF.2 |
Manifestations of DYT-SPR typically begin earlier than those in GTPCH1-deficient DRD. Early-onset Parkinson disease(See Parkin Type of Early-Onset Parkinson Disease, PINK1 Type of Young-Onset Parkinson Disease, and Parkinson Disease Overview.) | PINK17PRKN8 | AR | In the early course, the clinical differentiation between early-onset Parkinson disease w/dystonia GTPCH1-deficient DRD is difficult.; Persons w/early-onset Parkinson disease (esp those w/onset age 20 yrs) often develop gait disturbance (attributable to foot dystonia) as the initial symptom.9 |
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
Organ System | Evaluation | Comment
| Baseline neurologic exam | Important to assess severity of symptoms prior to starting levodopa administration
| Consultation w/clinical geneticist /or genetic counselor |
Treatment of Manifestations
Table 4.
Treatment of Manifestations in Individuals with GTPCH1-Deficient DRD
Manifestation | Treatment | Considerations/Other
Dystonia/
| Levodopa/DCI | • Initial suggested dose1,2,3 (a levodopa trial):• Children 6 yrs: 1-10 mg/kg levodopa/DCI daily, administered in multiple doses3
Children ≥6 years: 25-50 mg levodopa/DCI 1-3x/day
Adults: 50 mg levodopa/DCI 1-3x/day
Changing the dose slowly by small increments is recommended.
Motor benefit can be recognized immediately or w/in a few days of starting levodopa therapy; full benefit occurs w/in several days to a few months.
Maximum benefit (complete or near-complete responsiveness of symptoms) is generally achieved by 300-400 mg/day of levodopa/DCI.
Transient dyskinesias
assoc w/initiation
of treatment
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
Discontinuation of levodopa treatment usually results in return of symptoms.
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
Search ClinicalTrials.gov in the US and www.ClinicalTrialsRegister.eu in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"
1 trial found